ReviewJournal of neurology2021
COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?
Review in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Systematic review and evidence gap mapping of biomarkers associated with neurological manifestations in patients with COVID-19.Journal of neurology · 2024Pooled it
- Pooled it
- Heterogeneity in Regional Damage Detected by Neuroimaging and Neuropathological Studies in Older Adults With COVID-19: A Cognitive-Neuroscience Systematic Review to Inform the Long-Term Impact of the Virus on Neurocognitive Trajectories.Frontiers in aging neuroscience · 2021Pooled it
- The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study.PloS one · 2021Pooled it
- Neurodegenerative and Cognitive Consequences of Long COVID.International journal of molecular sciences · 2026Review
- Clinical Manifestations of Subjects with Long COVID and Their Associations with Drug Use: The BioICOPER Study.Biomedicines · 2026Article
- The interplay between stress, inflammation and Parkinson's disease: insights from the COVID-19 pandemic.NPJ Parkinson's disease · 2025Article
- Long-Term Effects of COVID-19 on Women's Reproductive Health and Its Association with Autoimmune Diseases, Including Multiple Sclerosis.Journal of clinical medicine · 2025Review
- Role of toll-like receptors in post-COVID-19 associated neurodegenerative disorders?Frontiers in medicine · 2025Review
- Neuroprotective Effects of Olive Oil: A Comprehensive Review of Antioxidant Properties.Antioxidants (Basel, Switzerland) · 2024Review
- Phenolic Compounds of Therapeutic Interest in Neuroprotection.Journal of xenobiotics · 2024Review
- Long COVID and its association with neurodegenerative diseases: pathogenesis, neuroimaging, and treatment.Frontiers in neurology · 2024Review
- Potential association between COVID-19 and neurological disorders: analysis of common genes and therapeutics.Frontiers in neurology · 2024Article
- Unveiling the Clinical Spectrum of Post-COVID-19 Conditions: Assessment and Recommended Strategies.Cureus · 2024Review
- Review
- SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein.Molecular psychiatry · 2023Article
- Assessment of early and long-COVID related retinal neurodegeneration with optical coherence tomography.International ophthalmology · 2023Article
- Managing dementia care during COVID-19 pandemic: caregivers' experiences in Odisha, India.Primary health care research & development · 2023Article
- Shared miRNA landscapes of COVID-19 and neurodegeneration confirm neuroinflammation as an important overlapping feature.Frontiers in molecular neuroscience · 2023Article
- Brain Renin-Angiotensin System: From Physiology to Pathology in Neuronal Complications Induced by SARS-CoV-2.Analytical cellular pathology (Amsterdam) · 2023Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurological disorders and coronavirus 2019 (COVID-19) pandemic are two conditions with a recent well-documented association. Intriguing evidences showed that COVID-19 infection can modify clinical spectrum of manifested neurological disorders but also it plays a crucial role in the development of future diseases as long-tem consequences. In this viewpoint review, we aimed to assess the vulnerability to SARS-CoV-2 infection and development of COVID-19 among neurological disorders. With this in mind, we tested the hypothesis that age rather than neuropathology itself could be decisive in neurodegenerative diseases such as Parkinson's disease, whereas neuropathology rather than age may be critical in neuroimmunological diseases such as Multiple Sclerosis. Highlighting the role of potential susceptibility or protection factors from this disastrous infection, we also stratify the risk for future neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.